|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, whether serum glycosylation isomer of M2BP (M2BPGi) was associated with the regression of liver fibrosis in patients with chronic hepatitis B (CHB) during IFN-α add-on therapy is still unknown.
|
30905065 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup> -M2BP) is a novel marker for staging liver fibrosis and predicting hepatocellular carcinoma (HCC) occurrence.
|
29732647 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA<sup>+</sup> -M2BP) can be used to assess the degree of liver fibrosis, but few studies have investigated its prognostic utility.
|
27973711 |
2017 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interferon-λ3 levels were significantly higher after viral clearance in patients who developed HCC and were associated with a higher potential for hepatocarcinogenesis, such as a higher frequency of non-hypervascular hypointensive nodules (P = 0.046), higher stages of liver fibrosis (P < 0.001), and higher post-treatment levels of Wisteria floribunda agglutinin positive Mac-2 binding protein (P < 0.001) and alanine aminotransferase (P < 0.001).
|
30623518 |
2019 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Linear regression analysis revealed that alanine aminotransferase (odds ratio [OR]: 0.03, 95% confidence intervals [CI]: 0.02-0.05, P < 0.001), AST (OR: -0.1, 95% CI: -0.02 to -0.01, P < 0.001), and liver fibrosis (OR: 0.30, 95% CI: 0.01-0.59, P = 0.043) were the independent factors correlated to serum WFA<sup>+</sup>-M2BP level.
|
28811008 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess the association between the serum glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup>-M2BP) for liver fibrosis and outcomes and carcinogenesis of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients with advanced fibrosis.
|
29491234 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi) was recently identified as a serum glycobiomarker for liver fibrosis.
|
29473206 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, mac-2 binding protein glycosylation isomer (M2BPGi), a biomarker for liver fibrosis, was reduced after the therapy.
|
28621007 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases.
|
30671807 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
M2BP was measured in 31 HIV/HCV co-infected patients, and we analyzed the correlation between WFA<sup>+</sup> -M2BP and several markers of fibrosis, liver function, and tumor markers.
|
31785125 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum WFA(+)-M2BP could predict liver fibrosis in both HBV and HCV infection.
|
28475652 |
2017 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The serum WFA(+) -M2BP level significantly increased with the progress of liver fibrosis.
|
26503582 |
2016 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate WFA+-M2BP level in assessing liver fibrosis in patients with chronic hepatitis B (CHB) infection.
|
31393964 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA<sup>+</sup> -M2BP) is a novel glycobiomarker for evaluating liver fibrosis, but less is known about its role in liver cirrhosis (LC).
|
29607614 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
The WFA<sup>+</sup> -M2BP values were significantly greater in NAFLD patients with HCC than in those without HCC among patients with liver fibrosis ≥stage 3.
|
29316028 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
For predicting F4, WFA<sup>+</sup> -M2BP level yielded the highest area under the receiver operating characteristic curve (AUROC) with a level of 0.87 and for predicting advanced liver fibrosis (≥F3) and significant liver fibrosis (≥F2), WFA<sup>+</sup> -M2BP level yielded the second highest AUROCs (both, 0.77) among six fibrotic markers.
|
26990490 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that serum WFA<sup>+</sup> -M2BP or type IV collagen 7S levels serve as useful independent markers for detecting significant fibrosis and that use of both WFA<sup>+</sup> -M2BP and type IV collagen 7S together increased the sensitivity and negative predictive value for the diagnosis of liver fibrosis.
|
29633352 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the utility of a novel fibrosis glycobiomarker Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA<sup>+</sup> -M2BP) for evaluating liver fibrosis and disease progression in patients with chronic HBV infection.
|
27300763 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum WFA<sup>+</sup> -M2BP values appear to be useful for assessing liver fibrosis stage and are independently associated with HCC development in patients with chronic HBV infection.
|
27029022 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
For predicting cirrhosis (F4) and advanced liver fibrosis (≥ F3), M2BPGi had higher areas under the curve (AUCs; 0.93, respectively) with cutoff COIs of 1.84 and 1.67, respectively, than for the four conventional markers for fibrosis.
|
30128700 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive mac-2 binding protein (WFA<sup>+</sup>-M2BP) is an excellent biomarker for predicting hepatic fibrosis.
|
27665173 |
2017 |
|
LGALS3BP
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In AIH group, serum galectin-9 levels weakly correlated with alanine aminotransferase levels or total bilirubin (TB) and strongly correlated with C-X-C motif chemokine 10 (CXCL10) and Mac-2 binding protein glycosylation isomer (M2BPGi) levels, but did not correlate with the histological grade of liver fibrosis.
|
31464928 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel marker for liver fibrosis.
|
30786068 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified Mac-2 (galectin-3) binding protein (Mac-2bp) as a novel diagnostic and liver fibrosis predicting biomarker for nonalcoholic steatohepatitis in humans.
|
27615366 |
2017 |
|
LGALS3BP
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A glycoproteomics study aimed at identifying such markers discovered Mac 2-Binding Protein Gylcan Isomer (M2BPGi), which is a reliable marker for assessing liver fibrosis in patients with viral hepatitis and other fibrotic liver diseases such as primary biliary cholangitis, biliary atresia, autoimmune hepatitis, and nonalcoholic fatty liver disease.
|
29318378 |
2018 |